The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women
NCT ID: NCT00141557
Last Updated: 2008-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
133 participants
INTERVENTIONAL
2004-07-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
esterified estrogens 1.25mg and methyltestosterone 2.5mg
ESTRATEST® administered orally QD
2
Esterified estrogens 1.25 mg
Esterified estrogens 1.25 mg administered orally QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
esterified estrogens 1.25mg and methyltestosterone 2.5mg
ESTRATEST® administered orally QD
Esterified estrogens 1.25 mg
Esterified estrogens 1.25 mg administered orally QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
35 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Solvay Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 66
Huntsville, Alabama, United States
Site 57
Mobile, Alabama, United States
Site 46
Montgomery, Alabama, United States
Site 29
Phoenix, Arizona, United States
Site 15
Tucson, Arizona, United States
Site 3
Jonesboro, Arkansas, United States
Site 22
Little Rock, Arkansas, United States
Site 68
Carmichael, California, United States
Site 55
Encinitas, California, United States
Site 6
San Diego, California, United States
Site 45
Santa Rosa, California, United States
Site 25
Walnut Creek, California, United States
Site 26
Denver, Colorado, United States
Site 1
Groton, Connecticut, United States
Site 54
Hartford, Connecticut, United States
Site 30
Trumbull, Connecticut, United States
Site 34
Waterbury, Connecticut, United States
Site 10
Aventura, Florida, United States
Site 78
Clearwater, Florida, United States
Site 73
Fort Myers, Florida, United States
Site 51
Leesburg, Florida, United States
Site 49
Melbourne, Florida, United States
Site 64
New Port Richey, Florida, United States
Site 61
Ocala, Florida, United States
Site 27
Palm Springs, Florida, United States
Site 11
Pinellas Park, Florida, United States
Site 75
Sarasota, Florida, United States
Site 69
St. Petersburg, Florida, United States
Site 70
Venice, Florida, United States
Site 17
West Palm Beach, Florida, United States
Site 50
Alpharetta, Georgia, United States
Site 5
Atlanta, Georgia, United States
Site 44
Decatur, Georgia, United States
Site 77
Douglasville, Georgia, United States
Site 9
Riverdale, Georgia, United States
Site 7
Savannah, Georgia, United States
Site 47
Boise, Idaho, United States
Site 24
Champaign, Illinois, United States
Site 20
Chicago, Illinois, United States
Site 76
Peoria, Illinois, United States
Site 58
Evansville, Indiana, United States
Site 39
Wichita, Kansas, United States
Site 59
Baton Rouge, Louisiana, United States
Site 52
New Orleans, Louisiana, United States
Site 53
Ann Arbor, Michigan, United States
Site 63
Kansas City, Missouri, United States
Site 32
Richmond Heights, Missouri, United States
Site 36
St Louis, Missouri, United States
Site 72
Billings, Montana, United States
Site 21
Lincoln, Nebraska, United States
Site 37
Reno, Nevada, United States
Site 65
Cary, North Carolina, United States
Site 13
New Bern, North Carolina, United States
Site 16
Winston-Salem, North Carolina, United States
Site 60
Columbus, Ohio, United States
Site 67
Oklahoma City, Oklahoma, United States
Site 40
Tulsa, Oklahoma, United States
Site 62
Eugene, Oregon, United States
Site 41
Medford, Oregon, United States
Site 33
Portland, Oregon, United States
Site 18
Erie, Pennsylvania, United States
Site 19
Philadelphia, Pennsylvania, United States
Site 23
Pottstown, Pennsylvania, United States
Site 31
Anderson, South Carolina, United States
Site 35
Greer, South Carolina, United States
Site 4
Chattanooga, Tennessee, United States
Site 74
Conroe, Texas, United States
Site 8
Corpus Christi, Texas, United States
Site 71
Dallas, Texas, United States
Site 42
Houston, Texas, United States
Site 14
San Antonio, Texas, United States
Site 38
Salt Lake City, Utah, United States
Site 28
Norfolk, Virginia, United States
Site 12
Richmond, Virginia, United States
Site 56
Renton, Washington, United States
Site 2
Seattle, Washington, United States
Site 48
Spokane, Washington, United States
Site 43
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S030.2.110
Identifier Type: -
Identifier Source: org_study_id